Foghorn Therapeutics has appointed Carl Decicco to serve as its chief scientific officer. Decicco joins the Cambridge, MA, biotech from Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), where he was head of discovery. In addition to his executive role at Foghorn, Decicco will also serve as a venture partner at Flagship Pioneering, the venture capital firm that launched Foghorn earlier this year. Foghorn is developing cancer drugs meant to regulate and control gene expression.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
